Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Drug

AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma

Fineline Cube May 7, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...

Company Drug

Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial

Fineline Cube May 7, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company

Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025

Fineline Cube May 7, 2025

Germany-based Fresenius Medical Care (FRA: FMEA) released its 2025 Q1 financial report, showing total revenues...

Company Drug

Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME

Fineline Cube May 7, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...

Company Deals

EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology

Fineline Cube May 7, 2025

EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...

Company Medical Device

Beijing Wantai’s HIV Urine Self-Test Kit Gains WHO Prequalification

Fineline Cube May 7, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its HIV urine...

Company Deals

Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex for Mexico

Fineline Cube May 7, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the...

Company Drug

Shuangcheng Pharma’s Generic Bivalirudin Approved by Australia’s TGA

Fineline Cube May 7, 2025

China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...

Company Drug

Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment

Fineline Cube May 7, 2025

China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...

Company Deals

Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion

Fineline Cube May 6, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...

Company Drug

CSPC’s JMT202 Receives FDA IND Approval for Hypertriglyceridemia Trials

Fineline Cube May 6, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval...

Company Drug

Guilin Sanjin’s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials

Fineline Cube May 6, 2025

Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s...

Company Drug

Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025

Fineline Cube May 6, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...

Company Drug

AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment

Fineline Cube May 6, 2025

China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...

Company Drug

Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review

Fineline Cube May 6, 2025

Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...

Company Deals

Nanjing Perlove Medical Equipment Files IPO Application in Hong Kong

Fineline Cube May 6, 2025

China-based Nanjing Perlove Medical Equipment Co., Ltd., a specialist in medical imaging and surgical robotics,...

Company Deals

Sanofi’s Opella Becomes Independent Consumer Healthcare Company After CD&R Deal

Fineline Cube May 6, 2025

Opella, the consumer health business of French pharmaceutical giant Sanofi (NASDAQ: SNY), became an independent...

Company Drug

Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis

Fineline Cube May 6, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...

Company Drug

Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial

Fineline Cube May 6, 2025

China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...

Policy / Regulatory

China’s 13 Ministries Release Guidance to Optimize Primary Healthcare Institutions

Fineline Cube May 6, 2025

The National Health Commission, National Development and Reform Commission, and State Commission Office of Public...

Posts pagination

1 … 185 186 187 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.